Value-Based Pricing Could Boost Global Applicability Of NICE Appraisals
This article was originally published in The Pink Sheet Daily
Value-based pricing will start in the U.K. in January 2014 for newly launched products, with prices taking into account innovation and societal benefit as well as NICE's usual clinical and cost-effectiveness analysis, U.K. Health Secretary Andrew Lansley tells NICE's annual conference.
You may also be interested in...
Sir Michael Rawlins talks about his views on EuroNICE, PCORI and the future of health technology assessment as he prepares to step down after nearly 14 years as chairman of the U.K.'s cost regulator, the National Institute for Health and Clinical Excellence.
With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.